Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering | Region

FORT LAUDERDALE, FL / ACCESS Newswire / May 18, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the “Company”), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.

The offering consisted of 12,000,000 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) two (2) Series C Warrants to purchase one (1) share of Common Stock per warrant at an initial exercise price of $0.50. The public offering price per Common Unit is $0.50 (or $0.49999 per Pre-Funded Unit, which is equal to the public offering price per Common Unit minus an exercise price of $0.00001 per share under the Pre-Funded Warrants). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. The Series C Warrants will be exercisable immediately and expire five years after the initial issuance date. The exercise price and number of shares issuable under the Series C Warrants are subject to adjustment as described in more detail in the final prospectus to be filed in connection with the offering.

kAm%96 EC2?D24E:@? 😀 6IA64E65 E@ 4=@D6 @? @C 23@FE |2J `h[ a_ae[ DF3;64E E@ E96 D2E:D724E:@? @7 4FDE@>2CJ 4=@D:?8 4@?5:E:@?D] %96 r@>A2?J 6IA64ED E@ FD6 E96 ?6E AC@4665D 7C@> E96 @776C:?8 7@C 86?6C2= 4@CA@C2E6 AFCA@D6D 2?5 H@C<:?8 42A:E2=]k^Am

kAmp68:D r2A:E2= r@CA] 😀 24E:?8 2D E96 6I4=FD:G6 A=246>6?E 286?E 7@C E96 @776C:?8] $:496?K:2 #@DD u6C6?46 r2C>6= {{! 😀 24E:?8 2D 4@F?D6= E@ E96 r@>A2?J] z2F7>2? U2>Aj r2?@=6D[ !]r] 😀 24E:?8 2D 4@F?D6= E@ p68:D r2A:E2= r@CA]k^Am

kAmp C68:DEC2E:@? DE2E6>6?E @? u@C> $\` W}@] bbb\ahdg__X AC6G:@FD=J 7:=65 H:E9 E96 &]$] $64FC:E:6D 2?5 tI492?86 r@>>:DD:@? WE96 Q$trQX @? |2J `a[ a_ae H2D 564=2C65 67764E:G6 3J E96 $tr @? |2J `g[ a_ae] %96 @776C:?8 😀 36:?8 >256 @?=J 3J >62?D @7 2 AC@DA64EFD] p 7:?2= AC@DA64EFD 56D4C:3:?8 E96 E6C>D @7 E96 @776C:?8 H:== 36 7:=65 H:E9 E96 $tr 2?5 H:== 36 2G2:=23=6 @? E96 $trVD H63D:E6 =@42E65 2E k2 9C67lQ9EEAi^^HHH]D64]8@GQmHHH]D64]8@Gk^2m] t=64EC@?:4 4@A:6D @7 E96 7:?2= AC@DA64EFD >2J 36 @3E2:?65[ H96? 2G2:=23=6[ 3J 4@?E24E:?8 p68:D r2A:E2= r@CA][ pEE6?E:@?i $J?5:42E6 s6A2CE>6?E[ `bcd pG6?F6 @7 E96 p>6C:42D[ afE9 7=@@C[ }6H *@C<[ }* `_`_d[ 3J 6>2:= 2E k2 9C67lQ>2:=E@iDJ?5:42E6o268:D42A]4@>QmDJ?5:42E6o268:D42A]4@>k^2m[ @C 3J E6=6A9@?6 2E Z` Wa`aX g`b\`_`_] q67@C6 :?G6DE:?8 😕 E9:D @776C:?8[ :?E6C6DE65 A2CE:6D D9@F=5 C625 😕 E96:C 6?E:C6EJ E96 AC@DA64EFD[ H9:49 AC@G:56D >@C6 :?7@C>2E:@? 23@FE E96 r@>A2?J 2?5 DF49 @776C:?8]k^Am

kAm%9:D AC6DD C6=62D6 D92== ?@E 4@?DE:EFE6 2? @776C E@ D6== @C 2 D@=:4:E2E:@? @7 2? @776C E@ 3FJ[ ?@C D92== E96C6 36 2?J D2=6 @7 E96D6 D64FC:E:6D 😕 2?J DE2E6 @C ;FC:D5:4E:@? 😕 H9:49 DF49 2? @776C[ D@=:4:E2E:@? @C D2=6 H@F=5 36 F?=2H7F= AC:@C E@ C68:DEC2E:@? @C BF2=:7:42E:@? F?56C E96 D64FC:E:6D =2HD @7 2?J DF49 DE2E6 @C ;FC:D5:4E:@?]k^Am

kAmp3@FE $F?D9:?6 q:@A92C>2 x?4]k^Am

kAm$F?D9:?6 q:@A92C>2 4FCC6?E=J >2C<6ED e_ 86?6C:4 AC6D4C:AE:@? 5CF8D 😕 r2?252[ H:E9 `a 255:E:@?2= =2F?496D A=2??65 7@C E96 C6>2:?56C @7 a_ae] %96 r@>A2?J 😀 2=D@ 25G2?4:?8 EH@ AC@AC:6E2CJ 5CF8 56G6=@A>6?E AC@8C2>Dik^Am

kF=mk=:mkAmz`]` >#}p[ 2? >#}p‑{:A:5 }2?@A2CE:4=6 E96C2A6FE:4 42?5:52E6 E2C86E:?8 =:G6C 42?46C]k^Amk^=:mk=:mkAm!{AC@ AC@E62D6 :?9:3:E@C[ 2 D>2==‑>@=64F=6 2?E:G:C2= 42?5:52E6 7@C $p#$‑C6=2E65 4@C@?2G:CFD :?764E:@?D]k^Amk^=:mk^F=m

kAmp55:E:@?2= :?7@C>2E:@? 😀 2G2:=23=6 2E k2 C6=lQ?@7@==@HQ 9C67lQ9EEADi^^AC]C6A@CE^=>G2]4@>k^2m]k^Am

kAmu@CH2C5\{@@<:?8 $E2E6>6?EDk^Am

kAm%9:D AC6DD C6=62D6 4@?E2:?D Q7@CH2C5\=@@<:?8 DE2E6>6?EDQ H:E9:? E96 >62?:?8 @7 $64E:@? afp @7 E96 $64FC:E:6D p4E @7 `hbb 2?5 $64E:@? a`t @7 E96 $64FC:E:6D tI492?86 p4E @7 `hbc[ 6249 2D 2>6?565] u@CH2C5\=@@<:?8 DE2E6>6?ED :?4=F56 2== DE2E6>6?ED E92E 5@ ?@E C6=2E6 D@=6=J E@ 9:DE@C:42= @C 4FCC6?E 724ED[ :?4=F5:?8 H:E9@FE =:>:E2E:@? DE2E6>6?ED C682C5:?8 E96 r@>A2?JVD AC@5F4E 56G6=@A>6?E 2?5 3FD:?6DD AC@DA64ED[ E96 4=@D:?8 @7 E96 @776C:?8[ 2?5 E96 FD6 @7 AC@4665D 7C@> E96 @776C:?8[ 2?5 42? 36 :56?E:7:65 3J E96 FD6 @7 H@C5D DF49 2D Q>2J[Q QH:==[Q Q6IA64E[Q QAC@;64E[Q Q6DE:>2E6[Q Q2?E:4:A2E6[Q QA=2?[Q Q36=:6G6[Q QA@E6?E:2=[Q QD9@F=5[Q Q4@?E:?F6Q @C E96 ?682E:G6 G6CD:@?D @7 E9@D6 H@C5D @C @E96C 4@>A2C23=6 H@C5D] u@CH2C5\=@@<:?8 DE2E6>6?ED 2C6 ?@E 8F2C2?E66D @7 7FEFC6 24E:@?D @C A6C7@C>2?46] %96D6 7@CH2C5\=@@<:?8 DE2E6>6?ED 2C6 32D65 @? :?7@C>2E:@? 4FCC6?E=J 2G2:=23=6 E@ E96 r@>A2?J 2?5 :ED 4FCC6?E A=2?D @C 6IA64E2E:@?D 2?5 2C6 DF3;64E E@ 2 ?F>36C @7 C:DA2?JVD 5@4F>6?ED 7:=65 H:E9 E96 $64FC:E:6D 2?5 tI492?86 r@>>:DD:@?] p4EF2= C6DF=ED >2J 5:776C D:8?:7:42?E=J 7C@> E9@D6 2?E:4:A2E65[ 36=:6G65[ 6DE:>2E65[ 6IA64E65[ :?E6?565[ @C A=2??65 2D 2 C6DF=E @7 E96D6 C:DA2?J 36=:6G6D E92E E96 6IA64E2E:@?D C67=64E65 😕 E96 7@CH2C5\=@@<:?8 DE2E6>6?ED 2C6 C62D@?23=6[ E96 r@>A2?J 42??@E 8F2C2?E66 7FEFC6 C6DF=ED[ A6C7@C>2?46[ @C 249:6G6>6?ED] tI46AE 2D C6BF:C65 3J 2AA=:423=6 =2H[ :?4=F5:?8 E96 D64FC:E:6D =2HD @7 E96 &?:E65 $E2E6D[ E96 r@>A2?J 5@6D ?@E :?E6?5 E@ FA52E6 2?J @7 E96 7@CH2C5\=@@<:?8 DE2E6>6?ED E@ 4@?7@C> E96D6 DE2E6>6?ED E@ 24EF2= C6DF=ED]k^Am

kAmr2>:==6 $6322=J[ ru~k^Am

kAms:C64E {:?6i d`c‑g`c‑_ceck^Am

kAmk2 C6=lQ?@7@==@HQ 9C67lQ>2:=E@i42>:==6]D6322=JoDF?D9:?63:@A92C>2]4@>Qm42>:==6]D6322=JoDF?D9:?63:@A92C>2]4@>k^2mk^Am

kAm$~rti $F?D9:?6 q:@A92C>2 x?4]k^Am

kAm’:6H E96 @C:8:?2=k^Am

k2 9C67lQ9EEADi^^HHH]2446DD?6HDH:C6]4@>^?6HDC@@>^6?^962=E942C6\2?5\A92C>246FE:42=^DF?D9:?6\3:@A92C>2\:?4]\2??@F?46D\AC:4:?8\@7\e]_\>:==:@?\AF3=:4\@776C\“effegQmAC6DD C6=62D6k^2m

kAm@? prrt$$ }6HDH:C6k^Am

Copyright 2026 ACCESS Newswire. All Rights Reserved.